I have to say I think that all the folks I come across on this message board seem to understand how it works. You're free to disagree with that. If you're so concerned that you're being taken for a ride because investor who lend millions are profiting over their lending power. It is how it works. Anyone who doesn't like it then shouldn't invest in early stage biotech as it's not something that OTC companies can get around. They need to prove their worth to continue to fund. Eventually companies either make it to the main exchange and stay there or not, based on the merits of how they run the business and the pipeline. Those that have science that progresses eventually get to points where it straight non-dilutive funding. Companies can't skip steps. And companies often fail at various points. Some become extremely undervalued. Some become extremely over valued. It depends on the validations and sentiment along the way. You have the opportunity to get in early here. You won't know if you made the right choice until you can review in hindsight. So that's why DD is important. And collaborations with big Pharma over stage one early data (final not released yet) sort of helped many newcomers decision easier. Anyway, I wrote all this as complaining about the necessary double-edge sword of financing makes no sense this early on. I won't entertain it further. You're free to do it, but I won't participate. GL to you.
News 
Market Data 
Discover 
